Cortex gets OK to resume enrollment for Ampakine trials

Tue Jul 17, 2007 9:03am EDT
 
[-] Text [+]

July 17 (Reuters) - Cortex Pharmaceuticals Inc. (COR.A) said it has received approval from U.S. regulators to resume enrollment for clinical trials of its drug candidate, Ampakine CX717, in Alzheimer PET-scan studies .

The trial will resume at all dose levels.

The study of Ampakine CX717, which was originally designed with doses of 200mg, 600mg and 1200mg, was placed on hold by the U.S. Food and Drug Administration due to concerns over some preclinical animal data. (Reporting by Shailesh Kuber in Bangalore)

 
Join the Reuters Consumer Insight Panel and help us get to know you better

Join the Reuters Consumer Insight Panel and help us get to know you better